Semaglutide vs Retatrutide: UAE Research Comparison 2026
Published 23 June 2026 · REVIVE Peptides Research Desk · 10 min read
TL;DR. Semaglutide is a single GLP-1 agonist (Ozempic, Wegovy) — approved, well-established, ~15% weight loss at 68 weeks. Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) — in phase 3, not approved, ~24% weight loss at 48 weeks (phase 2). Retatrutide is faster and deeper but the long-term safety dataset is years behind semaglutide.
The Two Generations
Semaglutide is the second-generation GLP-1 agonist (after liraglutide). It targets one receptor: GLP-1. Retatrutide is the next leap — a triple agonist that hits GLP-1, GIP, and glucagon receptors simultaneously. The pharmacological generations:
Plateau not yet reached at week 48 — curve still descending
Why Retatrutide Goes Deeper
Three pharmacological reasons retatrutide outperforms semaglutide on weight loss:
GIP agonism amplifies satiety. GIP works synergistically with GLP-1 in the hypothalamus, reducing food intake beyond what GLP-1 alone can achieve.
Glucagon agonism raises energy expenditure. Basal metabolic rate increases modestly — meaning weight loss isn't purely intake-driven but also output-driven.
Hepatic fat targeting. The glucagon component preferentially mobilises liver fat, an effect semaglutide produces only secondarily through total weight loss.
Side Effects — Similar GI Profile, Different Cardiac
Side effect
Semaglutide
Retatrutide
Nausea
Common
Common
Vomiting
Less common
Less common
Diarrhoea
Common
Common
Constipation
Common
Common
Heart rate rise
Mild (+2 bpm)
Moderate (+6–8 bpm)
Gallbladder events
Slight increase
Slight increase
Hypoglycaemia (non-diabetic)
Rare
Rare
The heart rate elevation with retatrutide is the most-watched difference — attributed to glucagon agonism. Phase 2 data showed no clinical cardiac events but phase 3 long-term cardiac monitoring is ongoing.
If you need approved, prescribable weight loss treatment: semaglutide is the clear path. Approved, established, longest safety record.
If you're running peptide research and want maximum weight-loss data: retatrutide has phase 2 effect sizes 50%+ larger than semaglutide.
If safety record matters most: semaglutide has years more human data.
If hepatic fat is the research target: retatrutide hits it directly via glucagon agonism.
Researching retatrutide in the UAE?
REVIVE supplies retatrutide 5 mg and 10 mg vials with HPLC certificates and cold-chain delivery. View retatrutide vials →
Research use only. Retatrutide supplied by REVIVE is labelled and sold strictly for in-vitro and research purposes — not for human consumption. Semaglutide (Ozempic, Wegovy) is a prescription medicine requiring medical supervision under UAE regulations.
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). N Engl J Med. 2021;384(11):989–1002.
Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971–984.
Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metab. 2022;34(9):1234–1247.